Study protocol of the Asian XELIRI ProjecT (AXEPT):a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the effcacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
metastatic colorectal cancer、combination therapy、clinical trial、hazard ratio、sample size
35
R73;O21
2017-02-12(万方平台首次上网日期,不代表论文的发表时间)
共8页
735-742